The press release highlighted that the characterization of ASCENIV's competitive position reflects a misunderstanding of ADMA's business model and its role as a late-line therapy for patients who are immune compromised and may not respond to vaccines. ADMA provided additional details regarding its inventory levels and demand data to counter the claims made in the short report. The company stated that stocking levels maintained by its distributors align with industry standards and reflect the long production cycle for ASCENIV.
ADMA's management believes that the allegations of channel stuffing are unfounded, as distributors must maintain a level of safety stock to ensure continuity of care for patients requiring immunoglobulin therapy. The company also noted that its distributors typically stock above the minimum required levels to mitigate potential supply chain disruptions.
In conclusion, ADMA Biologics is committed to transparency and aims to provide accurate information to its investors. The company encourages stakeholders to review its filings with the U.S. Securities and Exchange Commission for further details on its operations and financial health.
